Intertek Melbourn provides analytical and formulation services to pharma, biotech and drug delivery, with expertise in inhalation and other dosage forms. Services include performance testing, method development/validation, stability, CMC, formulation development and clinical manufacturing.
Intertek Melbourn, part of Intertek’s Pharmaceutical Services division, provides product performance testing, method development/validation, stability, CMC support, formulation development and clinical manufacturing capabilities to the pharmaceutical, biotechnology and drug delivery industries.
Intertek Melbourn has specialist skills and experience in analytical testing and formulation for inhaled and intranasal products (OINDPs) as well as all other dosage forms. Its services span preformulation and formulation, analytical support, method development and validation; stability studies, stability storage, GMP batch release testing and clinical trial materials manufacturing.
Intertek Melbourn was formed when Intertek Group acquired Melbourn Scientific in 2013. The parent company, Intertek Group plc, is headquartered in London, UK, and publicly traded on the London Stock Exchange (LON: ITRK). It has a network of more than 1,000 laboratories and offices and over 43,000 people in more than 100 countries, which deliver testing, inspection and certification solutions for its customers’ operations and supply chains across a range of industries worldwide.